Early promise for new antimalarial drug

December 12, 2002

Preliminary results of a study in this week's issue of THE LANCET suggest that there may be a new treatment option for people who have become resistant to conventional treatments for malaria.

Safe and effective antimalarial drugs with new methods of action are urgently needed as resistance to conventional drug therapies such as chloroquine and sulfadoxine/pyrimethamine has created a severe public-health problem, especially in sub-Saharan Africa.

The antibiotic fosmidomycin has been shown to be effective in laboratory studies by its inhibition of a key enzyme produced by the Plasmodium falciparum parasite. Peter Kremsner from the University of Tübingen, Germany, and colleagues administered the drug for 5, 4, or 3 days (1.2 g every 8hours), in nine, eight, and ten malaria patients in Gabon. The drug was well tolerated, and cure rates after two weeks were 89%, 88%, and 60%, for treatment durations of 5, 4, and 3 days, respectively. Parasite elimination and reduction in fever was rapid.

Peter Kremsner comments: "These data suggest that fosmidomycin is a safe and effective treatment for malaria in adult Africans if given for 4 days or more. Further studies on combinations of fosmidomycin with other antimalarial drugs are needed to assess its safety and efficacy in children and to boost efficacy while benefiting from a shorter and simpler treatment regimen."
-end-


Lancet

Related Malaria Articles from Brightsurf:

Clocking in with malaria parasites
Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

Read More: Malaria News and Malaria Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.